Cargando…
A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months after the initial treatment cycle and ach...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302273/ https://www.ncbi.nlm.nih.gov/pubmed/30622727 http://dx.doi.org/10.1177/2055217318819012 |